Category: disputed data

Solvent paper dissolves under heat of institutional investigation

Jced_coverA chemical engineering paper published in February has been retracted for data and authorship problems.

According to the retraction notice, the authors’ institutions investigated and found that not only was the data not reproducible, but “not all co-authors on the manuscript were aware of or agreed to the content and scientific conclusions in the article.”

Here’s the notice in the Journal of Chemical & Engineering Data for “Ionic Liquids as Promising Solvents for Biomass Derived Mannitol and Xylitol”: Continue reading Solvent paper dissolves under heat of institutional investigation

Structure fumble sinks second of author’s JACS papers

jacsat_v136i001.inddProof that organic chemistry is hard for everyone, not just pre-meds: A paper in the Journal of the American Chemical Society was retracted after the structures of compounds being studied were “misassigned.”

Another study by author Doo Ok Jang, also in JACS, was retracted in 2013 for the same reason; you can read our coverage here. Jang and Sang Yoon Kim published that one in 2008; the paper we’re talking about today was published in 2010 by Jang and Sung Jun Kim.

Here’s the notice for “Indium-Mediated Catalytic Enantioselective Allylation of N-Benzoylhydrazones Using a Protonated Chiral Amine:” Continue reading Structure fumble sinks second of author’s JACS papers

New method sinks newish paper…or does it?

cover_2009_BB_viz_biomassThe timing on a recent retraction of a paper from Biotechnology and Bioengineering makes it a bit difficult to figure out what happened, but here’s a try.

An article first published online May 16th by a group of researchers at Brown University was retracted on June 1st, apparently because a new and better method for analyzing the data was developed…at some point.

The timeline is not exactly clear from the retraction, though we’ve reached out to the author and publisher and will update with any new information.

Here’s the (paywalled) notice for “High-level production of 3-hydroxypropionatein Escherichia coli and Saccharomyces cerevisiae by introducing part of the 3-hydroxypropionate/4-hydroxybutyrate cycle from Metallosphaera sedula”:

Continue reading New method sinks newish paper…or does it?

Bearly believable: Water bear paper retracted for missing lab notebooks

Water bear, via Wikimedia Commons
Image via Wikimedia Commons

Tardigrades, the most hardy animals on or off planet Earth, can survive boiling, freezing, and even the ravages of outer space.

Unfortunately, some data on water bears’ memories proved to be less long-lasting, earning a retraction for a George Mason University researcher who also published the paper without alerting her co-workers ahead of time.

Here’s the notice for “Suspended animation: effects on short-term and long-term positive associative memory in Hypsibius dujardini,” which first appeared in Invertebrate Neuroscience: Continue reading Bearly believable: Water bear paper retracted for missing lab notebooks

“Irregularities” lead to retraction of paper on delirium

spcarecoverA paper on delirium in older adults has been withdrawn by a geriatric journal, after the clinical hospital notified the journal of problems in the data.

Here’s the notice for “Issues Associated with Delirium Severity Among Older Patients,” which first appeared in BMJ Supportive & Palliative Care: Continue reading “Irregularities” lead to retraction of paper on delirium

Hydrogen journal pulls palladium paper for data misuse

intjhydrogenenergyThe International Journal of Hydrogen Energy is retracting a 2013 article for what appears to be the misappropriation of data.

The paper,  titled “Hydrogen production by an anaerobic photocatalytic reforming using palladium nanoparticle on boron and nitrogen doped TiO2 catalysts,” was written by researchers from the Veltech Dr RR & Dr SR Technical University, in Chennai, India, and Arizona State University.

According to the abstract: Continue reading Hydrogen journal pulls palladium paper for data misuse

Serial figure fakers have expression of concern upgraded to a retraction

Another retraction has appeared up for frequent fliers Jun Li, Kailun Zhang and Jiahong Xia at Huazhong Science and Technology University in Wuhan, China.

We’ve covered them twice before, for a variety of retractions, corrections, and expressions of concern.

The retraction, in Clinical and Experimental Immunology, upgrades an expression of concern published earlier this year, and is the team’s fourth.

Here’s the notice for “CCR5 blockade in combination with rapamycin prolongs cardiac allograft survival in mice”: Continue reading Serial figure fakers have expression of concern upgraded to a retraction

PLoS ONE issues expression of concern when company won’t share bacterial strain

plosoneThe editors of PLoS ONE have issued an expression of concern for a 2014 article on a form of nitrogen-fixing bacteria called Bacillus pumilus.

The reason: The company that provided the strain of microbe used in the research won’t let other researchers look at the organism.

The article is titled “Bacillus pumilus Reveals a Remarkably High Resistance to Hydrogen Peroxide Provoked Oxidative Stress,” and it came from a group led by Stefan Handtke, of the University of Greifswald, in Germany.

Here’s the notice: Continue reading PLoS ONE issues expression of concern when company won’t share bacterial strain

Faked figure sinks paper on potential new MRI contrast agent

langd5_v030i025.inddSurface chemistry journal Langmuir has retracted an article on a new MRI contrast agent — but only one of the authors agreed.

According to the notice:

Continue reading Faked figure sinks paper on potential new MRI contrast agent

Pfizer retracts another experimental cancer drug study

clin cancer researchPfizer has retracted another study involving an experimental cancer drug that later failed later-stage trials.

The study, published in Clinical Cancer Research in 2010, looked at which patients might respond to the drug, called figitumumab. Here’s the notice: Continue reading Pfizer retracts another experimental cancer drug study